Amgen Inc. (AMGN)
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw Amgen (AMGN) settling at $341.66, representing a -1.78% change from its previous close.
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent American Diabetes Association (ADA) Scientific Sessions in New Orleans.
Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?
MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.
Amgen Inc. (AMGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amgen Inc. (AMGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amgen Eyes 2026 ‘Springboard' as Growth Drugs Offset Patent Pressure
Amgen NASDAQ: AMGN executives said the company's first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen: Time For An Upgrade? Yes, I Think So
Amgen Inc. is upgraded to a cautious Buy, reflecting improved fundamentals, a diversified pipeline, and a decent risk/reward profile despite recent underperformance versus the S&P. Key growth drivers include Imdelltra, Uplizna, Tepezza, Repatha, and the promising but unproven Maritide, offsetting declines from legacy drugs like Prolia. AMGN's robust R&D pipeline, margin expansion, and capital investments are positioning the company for sustained long-term growth, though high debt and capex warrant monitoring.
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference
Amgen NASDAQ: AMGN executives used a Jefferies investor conference appearance to emphasize the company's first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide.
Amgen Inc. (AMGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Amgen Inc. (AMGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
